Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Effect of a Selective Steroid Receptor Agonist (SEGRA) on Keratoplasty

Pleyer U.1, Yang J.1, Knapp S.2, Schäcke H.4, Schmees N.4, Orlic N.1, Otasevic L.1, De Ruijter M.1, Ritter T.3
1Department of Ophthalmology, 2Institute of Pharmacy, 3Institute of Medical Immunology, Charité, Humboldt University, Berlin; 4Schering AG

Purpose: New insights into the molecular mechanisms of corticosteroid-mediated actions have revealed new substances, such as selective steroid receptor agonists (SEGRA) for the treatment of inflammatory diseases. To evaluate the effect of SEGRA following topical application on the clinical course of experimental orthotopic corneal grafts.
Method: A total of 18 female Lewis rats received 3.5 mm MHC I/II incompatible corneal grafts of DA donors. Recipients were randomly assigned to receive either (1) no therapy, (2) cyclodextrin-encapsulated SEGRA or vehicle (3). All treatments started at the day of surgery and were applied five time daily for 35 days. Grafts were graded every day and a rejection score was generated based on cornea clarity and oedema.
Results: Treatment with SEGRA was effective in prolonging the mean survival time (MST) of corneal grafts as compared to untreated controls or vehicle application.
Treatment           MST            


Zurück | Back